Thermogenesis (Nasdaq: KOOL, D: 883496) kaufen! Top-News und in D sogar unter Pari - 500 Beiträge pro Seite

[Ichtradegern]

Thermogenesis (Nasdaq: KOOL, D: 883496) könnte heute laufen. In Amerika vorbörslich schon bei 2 Dollar Geld und in Frankfurt noch bei 1,8 Euro Brief.
Haben einen großen Auftrag aus Korea bekommen.
Kursziel heute 2,30 Dollar.

Hier die Nachricht:
Rapidly Growing Cord Blood Stem Cell Market in Asia Creating Strong Demand For BioArchive(R) System
Monday March 24, 6:10 am ET
New Korean Cord Blood Stem Cell Bank Chooses BioArchive(R) System


RANCHO CORDOVA, Calif., March 24 /PRNewswire-FirstCall/ -- THERMOGENESIS CORP. (Nasdaq: KOOL - News), announced today that the Company has received its seventh BioArchive order from Korea. The system was ordered by the Company`s distributor Mirr SciTech, for installation at a new Cord Blood Bank being formed by Boryung Biopharm in Korea. The new Cord Blood Bank will be the sixth Korean Cord Blood Stem Cell Bank to select the BioArchive System for their cord blood program.
ADVERTISEMENT


Kevin Simpson, President and COO of THERMOGENESIS CORP. said that, "This is our third order from Korea this quarter and is evidence that this region is and will continue to be an important driver of our BioArchive business as new cord blood stem cell banks choose the BioArchive System to cryopreserve and archive their growing inventories of cord blood samples. Our customer base in Asia now includes twenty cord blood banks in seven countries."

Mr. Simpson further noted that, "We expect to see continued demand for BioArchive in Asia as this area of the world has been under served by traditional bone marrow registries. Cord blood serves as a readily available source of stem cells for bone marrow rescue for hematological cancers and genetic diseases such as Thalassemia, which occurs at an incredibly high rate in Asia. Further, recent research suggests that there are stem cells in cord blood that have the potential to produce other cells outside the hematopoietic system such as neural, liver, heart and bone cells. Because there are serious ethical issues with sourcing stem cells from embryos and fetuses, scientists appear to be focusing on cord blood as a non-controversial source for these multi-potential stem cells."

The BioArchive System plays a key role in the emerging world standards that are being adopted for the processing and validation of stem cell units. It provides sterile cell processing disposables and a computer-driven robotic system to allow users to cryopreserve and archive up to 3,626 units of blood components in -196 degrees C liquid nitrogen. The BioArchive System can cryopreserve, archive and retrieve samples within liquid nitrogen without exposing the samples to detrimental transient warming events (TWE), which can reduce cell viability.

Regulatory Status

The BioArchive System is a Class II blood and blood component freezer exempt from the pre-market notification procedures. The BioArchive System has potential applications involving archiving, storing, managing and retrieving other kinds of biological specimens, that may include stem cells, dendritic cells, T-cells, cell lines, sperm cells, eggs, heart valves, corneas, virus samples, biopsy samples and other blood, tissue and saliva samples. The BioArchive System is currently intended for storage of blood and blood components. Additional indications for use would require U.S. FDA clearance or approval.

About THERMOGENESIS CORP.

THERMOGENESIS CORP. has been a pioneer in designing, manufacturing and marketing micro-manufacturing systems which utilize robotic devices and sterile disposable bag sets to collect, cryopreserve and archive blood products such as hematopoietic stem cells, fibrin sealant and other related blood products from single units of donor blood.

The statements contained in this release which are not historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond the company`s control with respect to market acceptance of new technologies and products, delays in testing and evaluation of products, and other risks detailed from time to time in the Company`s filings with the Securities and Exchange Commission.




--------------------------------------------------------------------------------
Source: THERMOGENESIS CORP.

Email this story - Set a News Alert

[thebull 2]

wieder nen supertip der nix brachte
warum gibst du nicht einfach auf und hörst auf die tradingthreads zuzuspammen???
du merkst doch das du dich so langsam lächerlich machst
#1 von Ichtradegern Userinfo Nachricht an User 24.03.03 14:43:24 Beitrag Nr.: 8.971.050 8971050
Dieses Posting: versenden | melden | drucken | Antwort schreiben
Thermogenesis (Nasdaq: KOOL, D: 883496) könnte heute laufen. In Amerika vorbörslich schon bei 2 Dollar Geld und in Frankfurt noch bei 1,8 Euro Brief.
Haben einen großen Auftrag aus Korea bekommen.
Kursziel heute 2,30 Dollar.
schluss 1,63$
aber wenigsens postest du "könnte heute laufen"
aber,morgen "könnte" dies und das auch laufen
gebs auf,das bringt nix